<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151379">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01924689</url>
  </required_header>
  <id_info>
    <org_study_id>BVDCNV2</org_study_id>
    <nct_id>NCT01924689</nct_id>
  </id_info>
  <brief_title>Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies</brief_title>
  <official_title>Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMed Valley Discoveries, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMed Valley Discoveries, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol will examine the safety of intratumoral administration of Clostridium Novyi-NT
      spores in patients with treatment-refractory solid tumor malignancies. This investigational
      study will measure anti-tumor activity of C. novyi-NT administered intratumoral in patients
      with treatment-refractory solid tumor malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability of C. novyi-NT spore administration in patients with advanced solid tumor malignancies will be measured over a 8-day inpatient admission with routine labs, imaging (CT or MRI) assessments and continuous adverse event assessments.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity of C. novyi-NT spores will be assessed with serial imaging studies such as CT scans, MRI and blood-based tumor markers.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the C. novyi-NT spores will be measured in routine blood sampling over the course of the study.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The host immune and inflammatory response to C. novyi-NT spores will be measured in routine blood sampling over the course of the study.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Solid Tumor Malignancies</condition>
  <arm_group>
    <arm_group_label>Clostridium novyi-NT spores</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Clostridium novyi-NT spores</intervention_name>
    <description>Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.</description>
    <arm_group_label>Clostridium novyi-NT spores</arm_group_label>
    <other_name>bacteria</other_name>
    <other_name>anaerobic bacteria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of an advanced solid tumor malignancy. There must be a target tumor which
             is measureable, palpable or clearly identifiable under ultrasound or radiographic
             guidance and amenable to percutaneous injection of C. novyi-NT spores. The targeted
             lesion must have a longest diameter â‰¥ 1 cm and be measurable as defined by RECIST 1.1
             criteria.

          2. History of prior treatment with at least one line of systemic anticancer therapy,
             when an approved systemic therapy is available, and no curative option is available
             for continued treatment.

          3. At least 4 weeks have elapsed since the completion of major surgery, and the patient
             has fully recovered from this surgery and any post-surgical complications.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less (Appendix
             5: ECOG Performance Status Scale*).

          5. Patient is at least 18 years of age.

          6. Patient is capable of giving informed consent.

          7. Patient of childbearing potential (defined by the clinical sites' standards) is using
             adequate birth control measures (e.g., barrier method with spermicide; intrauterine
             device; implantable or injectable hormonal contraceptives; surgical sterilization)
             for the duration of the study and will continue to use such precautions for 12 months
             after receiving treatment.

          8. Patient has no significant valvular heart disease (trace or mild valvular stenosis or
             regurgitation is allowed).

          9. Patient is able to stay within 45 minutes driving time of an emergency room for 28
             days after doing.

         10. The patient has a caregiver for 28 days after dosing.

        Exclusion Criteria:

          1. Positive pregnancy test.

          2. Serum creatinine level &gt; 1.5 x the upper limit of normal (ULN), chronic renal failure
             requiring hemodialysis or peritoneal dialysis.

          3. Patient has any of the following hematologic parameters:

               -  Platelet count equal to or less than 100,000/mm3

               -  Hemoglobin less than 9.0 g/dL

               -  Absolute neutrophil count (ANC) less than 1,000 /mm3

          4. Oxygen saturation (Sp02) of less than 95% on room air.

          5. Mean arterial blood pressure (BP) of less than 70 mmHg.

          6. Glasgow Coma Score (GCS; see Appendix 3: SOFA Score Calculations) of less than 15.

          7. Treatment with an investigational drug within the past 30 days or 5 half-lives of
             that drug.

          8. Documented primary brain malignancy or brain metastases.

          9. Clinically significant ascites or clinical evidence or history of portosystemic
             hypertension or cirrhosis.

         10. Laboratory evidence of hepatic dysfunction indicated by any of the following:

               -  Bilirubin &gt; 1.5 x the ULN

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 2.5X
                  the ULN

               -  Alkaline phosphatase above 2.5X the ULN

               -  International normalized ratio (INR) greater than 1.3

         11. Patient has a foreign body which in the opinion of the treating investigator could be
             difficult to manage in case of infection (e.g. prosthetic hip).

         12. Clinically significant pleural effusion.

         13. Clinically significant pericardial effusion, circumferential pericardial effusion, or
             any effusion greater than 1.0 cm at any location around the heart.

         14. Need for ongoing treatment with an immunosuppressive agent.

         15. History of solid organ transplantation (with the exception of a corneal transplant &gt;
             3 months prior to screening).

         16. History of an ischemic insult in the previous 12 months (myocardial infarction,
             cerebral vascular accident, ischemic tissue from injury, transient ischemic attack.

         17. History of a significant medical illness deemed by the PI or local investigators as
             unsuitable for the trial. For example:

             i. Symptomatic congestive heart failure ii. Psychiatric Illness/social situation that
             may make study dangerous iii. Unstable angina pectoris

         18. Asplenia.

         19. Antibiotic allergies which would preclude treatment for a C. novyi-NT infection, in
             the event that antibiotics are required.

         20. Treatment with antibiotics within 2 weeks (14 days) of dosing.

         21. Active and clinically significant systemic or localized infection.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Saurabh Saha, MD, PhD</last_name>
    <phone>816-960-4661</phone>
    <email>ssaha@biomed-valley.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern - Robert H. Lurie Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Meservey</last_name>
      <phone>312-695-1387</phone>
    </contact>
    <contact_backup>
      <last_name>Sarika Jain, MD</last_name>
      <phone>312-695-0990</phone>
      <email>sarika.jain@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sarika Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kathy Elza-Brown, RN, OCN</last_name>
      <phone>410-502-5097</phone>
      <email>kelzabr1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Meyer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Schuetze, MD, PhD</last_name>
      <phone>734-647-8901</phone>
      <email>scotschu@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cancer Answer Line</last_name>
      <phone>1-800-865-1125</phone>
    </contact_backup>
    <investigator>
      <last_name>Scott Schuetze, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Trull</last_name>
      <phone>314-747-1864</phone>
      <email>trulll@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tonie Covelli</last_name>
      <phone>314-747-5543</phone>
      <email>covellit@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Wang-Gillam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanjay Goel, MD</last_name>
      <phone>718-904-2488</phone>
      <email>sgoel@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Mohammad Ghalib</last_name>
      <phone>718-405-8515</phone>
      <email>mhghalib@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sanjay Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mrinal Gounder, MD</last_name>
      <phone>646-888-4226</phone>
    </contact>
    <investigator>
      <last_name>Mrinal Gounder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelsey Kenny</last_name>
      <phone>216-444-1739</phone>
      <email>kennyk4@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Dale Shepard, MD, PhD</last_name>
      <phone>216-445-5670</phone>
      <email>shepard@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Dale Shepard, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorun Helgason</last_name>
      <phone>713-563-1193</phone>
      <email>thelgason@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Filip Janku, MD</last_name>
      <phone>713-563-1930</phone>
      <email>FJanku@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Filip Janku, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 9, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Metastatic Disease</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Malignancy</keyword>
  <keyword>Metastases</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Hypoxia</keyword>
  <keyword>Necrosis</keyword>
  <keyword>Intratumoral</keyword>
  <keyword>Locally advanced cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Chordoma</keyword>
  <keyword>Bacteriolytic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
